These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19786655)

  • 1. Biased hormonal therapy duration analysis makes results uninterpretable.
    Tangen CM; Goldman BH; Swanson GP; Thompson IM
    J Clin Oncol; 2009 Nov; 27(33):e203; author reply e204. PubMed ID: 19786655
    [No Abstract]   [Full Text] [Related]  

  • 2. Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapy.
    Collette L; Studer UE
    J Clin Oncol; 2009 Nov; 27(33):e201-2; author reply e204. PubMed ID: 19786659
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

  • 4. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 5. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
    Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
    Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection bias clouds apparent benefit of longer hormone duration.
    Lin K; Lee SP; Steinberg ML
    J Clin Oncol; 2010 Feb; 28(5):e79; author reply e80. PubMed ID: 19841313
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations].
    Newling DW
    Urologe A; 1995 Sep; 34(5):374-81. PubMed ID: 7483153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
    Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
    J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Fritz H. Schröder, Karl-Heinz Kurth, Sophie D. Fossa, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22.
    Drewa T
    Eur Urol; 2009 May; 55(5):e82-3. PubMed ID: 18950934
    [No Abstract]   [Full Text] [Related]  

  • 11. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: management of advanced disease.
    Droz JP; Fléchon A; Terret C
    Ann Oncol; 2002; 13 Suppl 4():89-94. PubMed ID: 12401672
    [No Abstract]   [Full Text] [Related]  

  • 13. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer.
    Bolla M; Descotes JL; Artignan X; Fourneret P
    BJU Int; 2007 Jul; 100 Suppl 2():44-7. PubMed ID: 17594359
    [No Abstract]   [Full Text] [Related]  

  • 16. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
    Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
    Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?
    Akaza H
    Can J Urol; 2005 Feb; 12 Suppl 1():77-80. PubMed ID: 15780172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer chemotherapy: emerging from the shadows.
    Roth BJ
    J Clin Oncol; 2005 May; 23(15):3302-3. PubMed ID: 15738529
    [No Abstract]   [Full Text] [Related]  

  • 20. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
    Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
    Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.